Focus: Eikon Therapeutics is a biotechnology company leveraging single particle tracking technology to develop oncology and specialty therapeutics across multiple therapeutic areas. The company operates as a mid-stage biotech with active clinical programs in melanoma, solid tumors, and lung cancer.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Growing — net +8 jobs in 30d
19 jobs added vs 11 removed. Steady team buildout.
Recent layoff filing — 55 affected
Source: state DOL filings via Big Local News
Eikon offers platform differentiation and growth-stage opportunity for R&D and clinical professionals, but limited financial transparency and early-stage pipeline introduce execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Eikon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eikon Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No public warning signs or FDA enforcement actions detected; primary risk is financial runway and clinical trial execution rather than regulatory or compliance issues.
Recent peer-reviewed publications with author affiliations at this company
Better reporting is better science: Community-defined minimal reporting requirements for light microscopy.
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo